These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 20651244)

  • 21. Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma.
    Wilkinson ST; Vanpatten KA; Fernandez DR; Brunhoeber P; Garsha KE; Glinsmann-Gibson BJ; Grogan TM; Teruya-Feldstein J; Rimsza LM
    Blood; 2012 Feb; 119(6):1459-67. PubMed ID: 22167754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas.
    Lin J; Lwin T; Zhao JJ; Tam W; Choi YS; Moscinski LC; Dalton WS; Sotomayor EM; Wright KL; Tao J
    Leukemia; 2011 Jan; 25(1):145-52. PubMed ID: 20966935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The significance of FOXP1 in diffuse large B-cell lymphoma.
    Gascoyne DM; Banham AH
    Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blimp-1 protein and Hans classification on prognosis of diffuse large B-cell lymphoma and their interrelation.
    Song Y; Cao Z; Li L; Zhang HT; Zhang X
    Chin J Cancer; 2010 Sep; 29(9):781-6. PubMed ID: 20800019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
    Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of microRNA expression characterize stages of human B-cell differentiation.
    Zhang J; Jima DD; Jacobs C; Fischer R; Gottwein E; Huang G; Lugar PL; Lagoo AS; Rizzieri DA; Friedman DR; Weinberg JB; Lipsky PE; Dave SS
    Blood; 2009 May; 113(19):4586-94. PubMed ID: 19202128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential epigenetic regulation between the alternative promoters, PRDM1α and PRDM1β, of the tumour suppressor gene PRDM1 in human multiple myeloma cells.
    Romero-García R; Gómez-Jaramillo L; Mateos RM; Jiménez-Gómez G; Pedreño-Horrillo N; Foncubierta E; Rodríguez-Gutiérrez JF; Garzón S; Mora-López F; Rodríguez C; Valor LM; Campos-Caro A
    Sci Rep; 2020 Sep; 10(1):15899. PubMed ID: 32985591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma.
    Garcia JF; Roncador G; García JF; Sánz AI; Maestre L; Lucas E; Montes-Moreno S; Fernandez Victoria R; Martinez-Torrecuadrara JL; Marafioti T; Mason DY; Piris MA
    Haematologica; 2006 Apr; 91(4):467-74. PubMed ID: 16585013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.
    Franco R; Scognamiglio G; Valentino E; Vitiello M; Luciano A; Palma G; Arra C; La Mantia E; Panico L; Tenneriello V; Pinto A; Frigeri F; Capobianco G; Botti G; Cerchia L; De Chiara A; Fedele M
    Oncotarget; 2016 Sep; 7(37):59158-59172. PubMed ID: 27494852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.
    Wang X; Cao X; Sun R; Tang C; Tzankov A; Zhang J; Manyam GC; Xiao M; Miao Y; Jabbar K; Tan X; Pang Y; Visco C; Xie Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WWL; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Winter JN; Piris MA; Li S; Miranda RN; Medeiros LJ; Li Y; Xu-Monette ZY; Young KH
    Neoplasia; 2018 Jun; 20(6):574-593. PubMed ID: 29734016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
    Farina FM; Inguscio A; Kunderfranco P; Cortesi A; Elia L; Quintavalle M
    Cell Death Dis; 2017 Jun; 8(6):e2890. PubMed ID: 28640256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses.
    White CA; Pone EJ; Lam T; Tat C; Hayama KL; Li G; Zan H; Casali P
    J Immunol; 2014 Dec; 193(12):5933-50. PubMed ID: 25392531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blimp-1 is a tumor suppressor gene in lymphoid malignancies.
    Hangaishi A; Kurokawa M
    Int J Hematol; 2010 Jan; 91(1):46-53. PubMed ID: 20047096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma.
    Lawrie CH; Chi J; Taylor S; Tramonti D; Ballabio E; Palazzo S; Saunders NJ; Pezzella F; Boultwood J; Wainscoat JS; Hatton CS
    J Cell Mol Med; 2009 Jul; 13(7):1248-60. PubMed ID: 19413891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypermethylation of the tumor suppressor gene PRDM1/Blimp-1 supports a pathogenetic role in EBV-positive Burkitt lymphoma.
    Zhang T; Ma J; Nie K; Yan J; Liu Y; Bacchi CE; Queiroga EM; Gualco G; Sample JT; Orazi A; Knowles DM; Tam W
    Blood Cancer J; 2014 Nov; 4(11):e261. PubMed ID: 25382611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Significance of miR-155, miR-34a and miR-30a expression in diffuse large B-cell lymphoma].
    Sun GX; Cao XS; Li Q; Wang Z; Peng J; Lu CQ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Feb; 30(1):79-83. PubMed ID: 23450486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma.
    Iqbal J; Sanger WG; Horsman DE; Rosenwald A; Pickering DL; Dave B; Dave S; Xiao L; Cao K; Zhu Q; Sherman S; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Ott G; Müller-Hermelink HK; Delabie J; Braziel RM; Jaffe ES; Campo E; Lynch JC; Connors JM; Vose JM; Armitage JO; Grogan TM; Staudt LM; Chan WC
    Am J Pathol; 2004 Jul; 165(1):159-66. PubMed ID: 15215171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth.
    Haery L; Lugo-Picó JG; Henry RA; Andrews AJ; Gilmore TD
    Mol Cancer; 2014 Feb; 13():29. PubMed ID: 24529102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The genetic deletion and protein expression of PRDM1 and its clinical implications in diffuse large B cell lymphoma: A retrospective cohort study in China.
    Nong L; Zheng Y; Li X; Li D; Liang L; Wang W; Li T
    Pathol Res Pract; 2022 May; 233():153860. PubMed ID: 35429891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blimp-1/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells.
    Kim JR; Mathew SO; Mathew PA
    Immunobiology; 2016 Jan; 221(1):31-9. PubMed ID: 26310579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.